USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Download PDF Copy

Reviewed

Melior DiscoveryJun 8 2010

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

"This recent patent notification offers the potential for robust patent protection for MLR-1023, Melior's lead drug candidate for diabetes, and represents a significant milestone for the Company," said Andrew Reaume PhD, President and CEO of Melior Discovery.

Source:

Melior Discovery

Posted in: Medical Condition News | Medical Patent News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Obesity-linked fat vesicles accelerate amyloid aggregation in Alzheimer’s disease

Building muscle shown to protect against obesity-related organ damage

Discovery of vascular-associated fibroblastic cells opens new path for diabetes treatment

Fatty acids found to be a primary driver of triple-negative tumor growth

SGLT-2 inhibitors offer protection against autoimmune conditions

Why improving LE8 scores could save young adults from diabetes

New AI tool detects bite rate to help prevent childhood obesity

Low-fat vegan diet shown to reduce insulin use and costs in type 1 diabetes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.